Valuation: Ind-Swift Laboratories Limited

Market Cap 2.93TCr 31Cr 28Cr 26Cr 23Cr 44Cr 45Cr 307.98Cr 122.81Cr 1.56TCr 117Cr 114.49Cr 4.94TCr P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 2.51TCr 27Cr 24Cr 22Cr 20Cr 38Cr 39Cr 263.7Cr 105.15Cr 1.34TCr 100.18Cr 98Cr 4.23TCr EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
32.35%
Yield 2025 *
-
Yield 2026 -
1 day+0.24%
1 week-1.19%
Current month-5.20%
1 month-3.28%
3 months+47.13%
6 months+151.95%
Current year+295.97%
1 week 331.85
Extreme 331.85
382
1 month 316
Extreme 316
426.6
Current year 87.25
Extreme 87.25
426.6
1 year 87.15
Extreme 87.15
426.6
3 years 68.72
Extreme 68.72
426.6
5 years 52.65
Extreme 52.65
426.6
10 years 15
Extreme 15
426.6
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/09/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%-1.19%+234.95%+268.78% 31Cr
-0.79%-4.48%+46.48%+118.69% 1,20600Cr
+1.43%+1.11%+48.05%+83.72% 66TCr
+1.07%-1.21%+32.92%+105.10% 51TCr
+1.52%-0.18%+42.17%+66.53% 38TCr
-0.14%-1.87%+70.06%+40.55% 36TCr
+0.88%+2.20%+31.53%+59.45% 31TCr
+1.64%+2.12%+7.83%+35.63% 29TCr
+0.03%-1.20%+43.79%+68.49% 25TCr
-0.41%-2.22%+40.43%+114.24% 21TCr
Average +0.89%-1.93%+59.82%+96.12% 41.8TCr
Weighted average by Cap. +1.14%-1.96%+42.49%+86.66%

Financials

2025 2026
Net sales 561.71Cr 5.98Cr 5.36Cr 4.9Cr 4.47Cr 8.42Cr 8.69Cr 59Cr 24Cr 299.72Cr 22Cr 22Cr 946.18Cr 649.14Cr 6.91Cr 6.19Cr 5.66Cr 5.17Cr 9.74Cr 10Cr 68Cr 27Cr 346.37Cr 26Cr 25Cr 1.09TCr
Net income 250.48Cr 2.66Cr 2.39Cr 2.18Cr 1.99Cr 3.76Cr 3.87Cr 26Cr 10Cr 133.65Cr 10Cr 9.79Cr 421.92Cr 43Cr 45.88L 41.15L 37.6L 34.33L 64.67L 66.71L 4.53Cr 1.81Cr 23Cr 1.72Cr 1.69Cr 73Cr
Net Debt -426.55Cr -4.54Cr -4.07Cr -3.72Cr -3.4Cr -6.4Cr -6.6Cr -45Cr -18Cr -227.6Cr -17Cr -17Cr -718.5Cr -421.25Cr -4.48Cr -4.02Cr -3.67Cr -3.35Cr -6.32Cr -6.52Cr -44Cr -18Cr -224.77Cr -17Cr -16Cr -709.58Cr
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
09/26/09 ₹349.05 +0.24% 5,18,533
08/26/08 ₹336.95 -3.23% 2,17,438
06/26/06 ₹348.20 -2.40% 3,54,791
05/26/05 ₹356.75 -3.72% 7,38,129
04/26/04 ₹370.55 +7.80% 6,85,300
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock